Lp(a) Cl23
ITXi012-A
General
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
External Databases (Donor) |
|
| BioSamples | SAMEA112366216 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Bertand Cariou (bertrand.cariou@univ-nantes.fr) |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Authorization number from the French Ministry of Health |
| Approval number | DC-2011-1399 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell line name | Lp(a) Cl23 |
| Source cell type |
An excreta material which is composed primarily of urine, a liquid excreta containing water and waste products made by the kidneys, stored in the bladder, and leaves the body through the urethra.; ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S.
|
| Source cell origin |
The fluid that is excreted by the kidneys. It is stored in the bladder and discharged through the urethra.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 4 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemMACS iPS-Brew medium
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| FOXA2 |
Yes |
Morphology
Endo_Meso_Ecto relative expression.pdf
ITXi012-A Differentiation capacity Endo, Meso et Ecto
In vitro directed differentiation
| Marker | Expressed |
| HAND1 |
Yes |
Morphology
Endo_Meso_Ecto relative expression.pdf
ITXi012-A Differentiation capacity Endo, Meso et Ecto
In vitro directed differentiation
| Marker | Expressed |
| PAX6 |
Yes |
Morphology
Endo_Meso_Ecto relative expression.pdf
ITXi012-A Differentiation capacity Endo, Meso et Ecto
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Unknown
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.